Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Se-Hyuk KimHeon YooJong Hee ChangChae-Yong KimDong Sup ChungSe-Hoon KimHye-Kyung ParkYoun Soo LeeSeung Ho YangPublished in: Journal of Korean medical science (2018)
The efficacy of procarbazine and CCNU chemotherapy is not satisfactory. This study suggests the need to develop other treatment strategies for recurrent and TMZ-refractory GBM. Trial registry at ClinicalTrials.gov, NCT017337346.